Replimune Group, Inc. (NASDAQ:REPL) Short Interest Update

Replimune Group, Inc. (NASDAQ:REPL - Get Free Report) saw a large increase in short interest during the month of January. As of January 31st, there was short interest totalling 8,470,000 shares, an increase of 16.7% from the January 15th total of 7,260,000 shares. Based on an average daily trading volume, of 885,200 shares, the days-to-cover ratio is currently 9.6 days.

Replimune Group Trading Down 1.8 %

Shares of NASDAQ:REPL traded down $0.25 during trading on Wednesday, reaching $13.78. 373,003 shares of the stock were exchanged, compared to its average volume of 741,697. Replimune Group has a 12-month low of $4.92 and a 12-month high of $17.00. The firm's 50-day moving average price is $12.61 and its 200 day moving average price is $11.81. The company has a debt-to-equity ratio of 0.14, a quick ratio of 11.43 and a current ratio of 11.43. The firm has a market cap of $1.06 billion, a price-to-earnings ratio of -4.49 and a beta of 1.30.

Replimune Group (NASDAQ:REPL - Get Free Report) last announced its earnings results on Wednesday, February 12th. The company reported ($0.79) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.70) by ($0.09). On average, sell-side analysts anticipate that Replimune Group will post -2.96 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, CEO Sushil Patel sold 10,000 shares of the firm's stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $12.42, for a total value of $124,200.00. Following the completion of the sale, the chief executive officer now owns 202,014 shares in the company, valued at $2,509,013.88. This trade represents a 4.72 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 8.80% of the stock is owned by insiders.

Hedge Funds Weigh In On Replimune Group

Several large investors have recently modified their holdings of the stock. Braidwell LP raised its position in shares of Replimune Group by 203.0% during the 3rd quarter. Braidwell LP now owns 3,070,837 shares of the company's stock valued at $33,656,000 after acquiring an additional 2,057,460 shares in the last quarter. Boxer Capital Management LLC acquired a new stake in Replimune Group in the fourth quarter worth $21,754,000. Tang Capital Management LLC lifted its position in Replimune Group by 125.0% in the 4th quarter. Tang Capital Management LLC now owns 2,700,000 shares of the company's stock valued at $32,697,000 after purchasing an additional 1,500,000 shares during the last quarter. State Street Corp boosted its position in shares of Replimune Group by 102.1% during the third quarter. State Street Corp now owns 2,340,042 shares of the company's stock worth $25,647,000 after buying an additional 1,182,181 shares during the period. Finally, Price T Rowe Associates Inc. MD grew its stake in shares of Replimune Group by 11.0% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 10,962,883 shares of the company's stock worth $132,761,000 after purchasing an additional 1,083,633 shares in the last quarter. Institutional investors own 92.53% of the company's stock.

Wall Street Analyst Weigh In

Several research firms recently commented on REPL. BMO Capital Markets boosted their price objective on shares of Replimune Group from $18.00 to $27.00 and gave the stock an "outperform" rating in a research report on Wednesday, January 22nd. HC Wainwright raised their price target on shares of Replimune Group from $21.00 to $22.00 and gave the stock a "buy" rating in a research note on Thursday, February 13th. Finally, Jefferies Financial Group upped their price objective on shares of Replimune Group from $16.00 to $19.00 and gave the company a "buy" rating in a research note on Wednesday, December 4th. Seven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and an average price target of $19.29.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.